Search results
Results from the WOW.Com Content Network
Diphenhydramine is a potent antimuscarinic (a competitive antagonist of muscarinic acetylcholine receptors) and, as such, at high doses can cause anticholinergic syndrome. [68] The utility of diphenhydramine as an antiparkinson agent is the result of its blocking properties on the muscarinic acetylcholine receptors in the brain.
The typical adult gains an average of 1 to 2 pounds per year, which over time, can contribute to obesity. This weight gain can be driven by physical inactivity, stress, poor sleep and poor food ...
One theory to explain antidepressant-related weight gain is that psychotropic medications such as antidepressants can affect neurotransmitters involved in eating behavior, causing an increase in ...
“Clinicians and patients can use this information, among other factors, to help decide on the right choice for them,” he added. Greatest risk of at least 5% weight gain at six months of use ...
In the most extreme cases, upward pressure on the diaphragm and lungs can also cause shortness of breath. Through a variety of causes (see below), bloating is most commonly due to buildup of gas in the stomach, small intestine, or colon. The pressure sensation is often relieved, or at least lessened, by belching or flatulence. Medications that ...
The most common symptom associated with bloating is a sensation that the abdomen is full or distended. Rarely, bloating may be painful or cause shortness of breath. [citation needed] Pains that are due to bloating will feel sharp and cause the stomach to cramp. These pains may occur anywhere in the body and can change locations quickly. [8]
For some people, Lexapro can cause weight loss, while for others, it may cause an increase in food intake and weight gain. Below, we’ve covered what Lexapro is, as well as why your mental health ...
Thiazolidinediones may cause slight weight gain but decrease "pathologic" abdominal fat (visceral fat), and therefore may be prescribed for diabetics with central obesity. [115] Thiazolidinedione has been associated with heart failure and increased cardiovascular risk; so it has been withdrawn from the market in Europe by EMA in 2010. [116]